Back to Stocks

MYGN

MYRIAD GENETICS INC
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Myriad Genetics is successfully transitioning from a legacy testing provider into a high-growth precision medicine platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a precision medicine pivot, Myriad's financial fundamentals reveal significant vulnerabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MYGN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing depicts a company at a crossroads, balancing promising clinical milestones against a tightening financial squeeze. While the launch of Precise MRD and the growth in Mental Health provide a credible path toward high-margin scalability, the immediate pressure of debt servicing and strict revenue covenants creates a high-stakes environment for investors. The disparity between volume growth and pricing trends in the cancer segment suggests a competitive landscape that may limit the company's ability to realize full pricing power. Ultimately, the impact of this filing hinges on the speed of the Precise MRD rollout. If Myriad can convert its clinical momentum into rapid revenue acceleration, it can comfortably satisfy its debt covenants and justify its precision medicine valuation. However, if the transition remains slow, the combination of negative operating cash flow and variable interest expenses could leave the company vulnerable to a liquidity crisis or a forced refinancing under unfavorable terms.

Selected Quarter

Core Takeaway

Myriad is successfully scaling new assays, but its financial flexibility is constrained by high-interest debt and a looming revenue floor required by lenders.

Investor Lens

The trade-off between long-term clinical validity (MRD launch) and short-term solvency (cash burn and debt covenants).

Watch Next

Quarterly revenue growth rates to ensure the company remains on track to meet the $615M trailing twelve-month revenue covenant.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%
bearishMay 6

Net loss widened to $34.1 million compared to $0.1 million in the prior year period.

earnings miss
70%
bearishMay 6

Revenue per test in the Cancer Care Continuum segment declined by 8%.

margin compression
40%
neutralMay 6

Utilization of a $125M term loan with a high variable interest rate of 10.2%.

debt restructure
50%
bullishMay 6

Successful launch of Precise MRD and 13% volume growth in Cancer Care.

guidance raise
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing depicts a company at a crossroads, balancing promising clinical milestones against a tightening financial squeeze. While the launch of Precise MRD and the growth in Mental Health provide a credible path toward high-margin scalability, the immediate pressure of debt servicing and strict revenue covenants creates a high-stakes environment for investors. The disparity between volume growth and pricing trends in the cancer segment suggests a competitive landscape that may limit the company's ability to realize full pricing power. Ultimately, the impact of this filing hinges on the speed of the Precise MRD rollout. If Myriad can convert its clinical momentum into rapid revenue acceleration, it can comfortably satisfy its debt covenants and justify its precision medicine valuation. However, if the transition remains slow, the combination of negative operating cash flow and variable interest expenses could leave the company vulnerable to a liquidity crisis or a forced refinancing under unfavorable terms.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.